Clinical Trial

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 9, 2026 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The overarching goals of this study are to measure levels of circulating tumor DNA (ctDNA) in patients with early stage diffuse large B cell lymphoma (DLBCL), to assess the change in ctDNA during treatment in order to prospectively identify markers of treatment failure, and to use ctDNA as a future tool for response adapted therapy.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2018-11-28; most recent amendment 2026-02-04.
Status change: Not Yet Recruiting → Recruiting 2019-05-09
Trial Details
NCT Number NCT03758989
Lead Sponsor University of Rochester
Conditions DLBCL
Enrollment 40 participants
Start Date 2019-05-08
Primary Completion 2026-06-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-09